Here is how Bavarian Nordic (BVNRY) and Dare Bioscience, Inc. (DARE) have performed compared to their sector so far this year.

The registrational trial is expected to support the Bavarian’s mpox/smallpox vaccine use in children between 2 and 11 years ...

Results from this study could support an extension of the current approval of MVA-BN to include children from 2 years of age ...

Is Bavarian Nordic (BVNRY) one of those stocks right now? Let's take a closer look at the stock's year-to-date performance to find out. Bavarian Nordic is a member of our Medical group ...

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest ...

One of the World Health Organization’s most important jobs is managing viral outbreaks. The rapid spread of mpox, a disease related to smallpox, is a reminder of its shortcomings. The WHO has ...

As the U.K. works to pump fresh cash into the local biopharma scene, London’s Accord Healthcare is capitalizing on the government’s renewed willingness to chip in. | Flush with a 50 million pound ...

One stock to keep an eye on is Bavarian Nordic (BVNRY). BVNRY is currently sporting a Zacks Rank of #2 (Buy), as well as an A grade for Value. Another notable valuation metric for BVNRY is its P/B ...

COPENHAGEN, Denmark, September 26, 2024 – Bavarian Nordic A/S (OMX: BAVA) upgrades its financial guidance for 2024. Based on today’s announced mpox vaccine order and additional orders secured, ...

The U.S. Food and Drug Administration has also approved Bavarian's shot, but only for use in adults 18 years and older, although it granted Emergency Use Authorization for its use in adolescents ...